venetoclax + pomalidomide + dexamethasone

Venetoclax + pomalidomide + dexamethasone is a **combination therapy of three small-molecule drugs**, each with complementary mechanisms, evaluated in relapsed/refractory multiple myeloma (RRMM), especially in patients refractory to lenalidomide[1][2]. Venetoclax is a selective BCL-2 inhibitor that induces apoptosis in BCL-2-dependent multiple myeloma cells. Pomalidomide is an immunomodulatory agent (IMiD) with antiangiogenic, antiproliferative, and immunomodulatory activity. Dexamethasone is a corticosteroid that increases BCL-2 dependency by modulating the expression of pro-apoptotic and anti-apoptotic proteins, thereby enhancing venetoclax activity[1][2][4]. The combination is under clinical investigation and is not currently an approved standard of care but shows activity, notably in lenalidomide-refractory patients. The combination is generally administered orally (venetoclax and pomalidomide daily, dexamethasone weekly in 28-day cycles)[1].

Other names

VenPd